I just listened to the presentation again. As well as mentioning PARP inhibitors at slide 7, Don lists 3 publications on slide 23 that suggest “a PARP inhibitor and a BET inhibitor are going to have a major impact in triple -ve breast cancer”. This is where Zenith will be starting wrt breast cancer in combo with a PARP inhibitor.